Skip to main content

tPA (Alteplase) Dosing for STEMI, Pulmonary Embolism & Stuck Prosthetic Valve



tPA (Alteplase) Dosing for STEMI, Pulmonary Embolism & Stuck Prosthetic Valve


tPA (alteplase) is a fibrin-specific thrombolytic used globally for rapid reperfusion in acute ischemic events. Unlike streptokinase, tPA has no antigenicity, works faster, and produces more targeted clot dissolution.


Below are the standard accepted alteplase regimens for:


STEMI


Acute Pulmonary Embolism


Prosthetic Valve Thrombosis (PVT / stuck valve)




---


1. Alteplase Dose for STEMI


Two main regimens are used: the accelerated 90-minute regimen (most common) and the 3-hour regimen.



---


A) Accelerated 90-Minute Regimen (Preferred)


Total dose: 100 mg


If weight ≥ 67 kg:


15 mg IV bolus


50 mg over 30 minutes


35 mg over the next 60 minutes



If weight < 67 kg:


15 mg IV bolus


Then 0.75 mg/kg over 30 minutes (max 50 mg)


Then 0.5 mg/kg over 60 minutes (max 35 mg)




---


B) 3-Hour Regimen (Alternative)


Total dose: 100 mg over 3 hours


1 mg/kg over 60 minutes


Then 1 mg/kg over the next 2 hours

(Max total 100 mg)



Used when accelerated protocol is not feasible.



---


2. Alteplase Dose for Acute Pulmonary Embolism


For massive PE (with hypotension, shock), tPA improves survival by rapidly reducing pulmonary pressures.


Standard PE Regimen


100 mg IV over 2 hours



(Heparin is held during infusion and restarted afterwards when aPTT < 2× normal.)



---


Alternative Low-Dose / Weight-Based Regimens


Used selectively in high-bleeding-risk patients:


50 mg over 2 hours


OR 0.6 mg/kg over 15 minutes (max 50 mg)



These are institution-dependent.



---


3. Alteplase for Stuck Prosthetic Valve (Prosthetic Valve Thrombosis)


tPA is often preferred over streptokinase because it is fibrin-specific, faster, and sometimes safer in controlled low-dose infusions.


There are three accepted clinical strategies:



---


A) “Ultraslow” Low-Dose Infusion (most endorsed today)


1 mg/hour for 25 hours (total 25 mg)

Followed by repeat cycles depending on response.



This approach (e.g., TROIA and PROMETEE protocols) reduces:


Major bleeding


Embolization


Need for surgery




---


B) Slow Infusion, Low Dose


25 mg alteplase infused over 6 hours


Repeat cycle up to 2–3 times if needed


No bolus



Used for left-sided valves, especially mitral.



---


C) Accelerated Regimen


Used in right-sided valves or when rapid thrombolysis is necessary.


10 mg bolus, then


90 mg infusion over 2 hours

(Max total 100 mg)



Higher embolization risk → used only in selected cases.



---


Summary Table


Condition Standard tPA Dose Alternative Dose


STEMI 100 mg (15 mg bolus → 50 mg/30 min → 35 mg/60 min) 100 mg over 3 hours

PE 100 mg over 2 hours 50 mg over 2 hr OR 0.6 mg/kg over 15 min

Stuck Valve 1 mg/hr × 25 hr (ultraslow) 25 mg/6 hr OR 100 mg over 2 hr



Comments

Popular posts from this blog

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

2025 AHA/ACC Hypertension Guidelines Key points

  2025 AHA/ACC Hypertension Guidelines Explained: A Clear Summary for Clinicians and Students Hypertension remains one of the most significant contributors to cardiovascular morbidity and mortality worldwide. With continual refinement of evidence and risk-based strategies, the 2025 AHA/ACC Hypertension Guidelines bring an updated, practical approach that clinicians can use in daily practice. To make learning easier, I’ve created a clean and modern infographic summarizing all major recommendations. You can download it below and use it for study, teaching, or clinical reference. Download Infographic (PNG): 2025 Hypertension Guideline Infographic This post breaks down the key points from the guidelines and complements the infographic for a complete understanding. --- BP Categories: Understanding the Updated Thresholds The guidelines maintain the well-established classification of blood pressure: Normal: <120 / <80 Elevated: 120–129 / <80 Stage 1 Hypertension: 130–139 and/or 8...